Labcorp on Tuesday raised its annual profit forecast and beat estimates in the third quarter as the laboratory operator ...

Labcorp, one of the country’s largest providers of diagnostic medical testing services, announced today that it will offer ...

Labcorp delivered mixed third-quarter results, with higher sales and raised profit | Labcorp reported solid third-quarter ...

Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug ...

Q3 2025 Earnings Call Transcript October 28, 2025 Labcorp Holdings Inc. beats earnings expectations. Reported EPS is $4.18, ...

Guidance Updates -- Full-year 2025 revenue growth guidance was narrowed to 7.4%-8%, with Adjusted EPS guidance was set at $16 ...

AI-driven diagnostic efficiency streamlines lab test selection, reducing clinician workload and enhancing patient care at health systems.

Opportunities in the global fertility test market include rising demand due to lifestyle changes, delayed pregnancies, and ...

The Burlington, N.C., lab-services company on Thursday said the Elecsys pTau181 test, developed by Swiss drugmaker Roche Holding and approved for commercialization by the U.S. Food and Drug ...

Labcorp forecast lower annual revenue growth for its contract research unit on Tuesday, as a prolonged funding crunch continues to weigh on its early-stage drug development clients.

BLS revenue reached $799 million, up 8.3%, and adjusted operating income grew to $132 million. The quarter ended with an $8.6 billion backlog, and the BLS book-to-bill was 0.89 for the quarter and ...